摘要
目的观察甘精胰岛素联合口服降糖药物治疗2型糖尿病的临床疗效和安全性。方法选择口服降糖药物血糖控制不佳的56例老年2型糖尿病患者,随机分为加用甘精胰岛素治疗组和低精蛋白锌胰岛素组两组,观察治疗前和治疗24周后各组的FBG、P2hBG、HbA1c和BMI的变化。同时对两种方案的安全性进行比较。结果治疗24周后甘精胰岛素组与低精蛋白锌胰岛素组均能降低FBG、P2hBG、HbA1c,且疗效相当,组内治疗前后比较差异无统计学意义,而BMI均没有明显变化。但甘精胰岛素组的严重低血糖发生率明显低于低精蛋白锌胰岛素组。结论甘精胰岛素组与低精蛋白锌胰岛素组在降低血糖方面的疗效相当,但甘精胰岛素组比低精蛋白锌胰岛素组治疗安全性高。
Objective To evaluate the clinical observation of therapeutic efficiency and safty of insulin glargine combined with oral hypoglycemic agents in elderly patients with type 2 diabetes.Methods Fifty six elderly patients with type 2 diabetes and poorly glycemic control by oral medication were randomly divided into two groups：insulin glargine（＋） group and isophane insulin（＋） group.FBG,P2hBG,HbA1c and BMI in each group were measured before and after 24 weeks of treatment,and the adverse effect were also recorded.Results HbA1c,FBG and P2hBG of the two groups were declined obviously after 24 weeks of treatment,and the therapeutic equivalence between the two groups.No significant change of BMI in the two groups.But the incidence of severe hypoglycemia in the insulin glargine group was lower than that in the isophane insulin group.Conclusion The therapeutic equivalence of insulin glargine and isophane insulin in decreasing the blood sugar was observed,but the security in insulin glargine group was higher than that in the low protamine zinc insulin group.
出处
《中华全科医学》
2011年第11期1680-1681,共2页
Chinese Journal of General Practice
